Integrated Collaborative Care for Substance Use Disorders

药物滥用障碍的综合协作护理

基本信息

  • 批准号:
    8677857
  • 负责人:
  • 金额:
    $ 81.01万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-07-01 至 2017-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Most individuals with opiate and alcohol-use disorders (OAUD) do not receive treatment. Primary care is an ideal setting in which to deliver OAUD treatment, yet evidence-based OAUD treatment is rarely provided. Barriers to delivery include insufficient organizational support and lack of provider role models and clinical support. We propose to evaluate the effectiveness of two strategies for increasing use of evidence-based treatment for OAUD within primary care: integrated collaborative care (ICC) and education and resources (E&R). While both strategies provide primary care practices with the same clinical information, ICC addresses these barriers by including organizational and technical support for delivering evidence-based care. ICC is grounded in the chronic care model and includes a behavioral health provider working as part of the care team. Essential elements of ICC strategy include a decision support component to help providers with complex patients, and a restructuring of the delivery and clinical information systems to support the delivery of evidence-based care. Our approach to implementing ICC is based on the organizational transformation model and quality improvement. We define the E&R strategy as providing printed educational materials and access to resources along with provider education. Both strategies are designed to increase the delivery of two evidence-based practices: motivational enhancement therapy and medication assisted therapy. We propose a 5-year mixed methods study and will conduct a RCT, with randomization occurring at the level of the care team and patient. We partner with 5 Venice Family Clinic (VFC) clinics, two hospitals in LA County, and COPE Health Solutions. VFC is a large federally qualified health center (FQHC) and the largest free clinic in the United States. Our approach includes document review, focus groups, interviews, and surveys for obtaining data on the adoption process and implementation outcomes; analysis of patient records and patient surveys on service system and patient outcomes; and analysis of provider financial records and patient records and surveys for estimating costs. We will enroll 400 patients with an OAUD diagnosis and follow them at 3 and 12 months. Our specific aims are: 1) To measure the process and extent of ICC and E&R implementation; 2) To test the effectiveness of ICC compared to an E&R strategy in promoting A. Implementation outcomes B. Service system outcomes and C. Patient outcomes; and 3) To estimate provider costs for each strategy. We define implementation outcomes as measures of the acceptability, adoption, appropriateness, feasibility, and sustainability of evidence-based OAUD treatment. We define service system outcomes as 1) process measures of treatment quality and 2) treatment co-morbidities. We define patient outcomes as hospital readmissions, OAUD outcomes, patient functioning, negative consequences from substance use, and unmet need. We define cost outcomes as start-up costs, operating costs and medical/psychiatric cost offsets.
描述(由申请人提供):大多数阿片类药物和酒精使用障碍(OAUD)患者未接受治疗。初级保健是提供OAUD治疗的理想环境,但很少提供循证OAUD治疗。提供服务的障碍包括组织支持不足以及缺乏提供者榜样和临床支持。我们建议评估两种策略的有效性,以增加使用循证治疗OAUD在初级保健:综合协作护理(ICC)和教育和资源(E&R)。虽然这两种策略提供相同的临床信息的初级保健实践,ICC解决这些障碍,包括提供循证护理的组织和技术支持。ICC以慢性病护理模式为基础,包括作为护理团队一部分的行为健康提供者。ICC战略的基本要素包括一个决策支持组件,以帮助复杂患者的提供者,并重组交付和临床信息系统,以支持循证护理的交付。我们实施ICC的方法是基于组织转型模式和质量改进。我们将E&R战略定义为提供印刷的教育材料和沿着资源以及提供者教育。这两种策略的目的是增加两个循证实践的交付:动机增强治疗和药物辅助治疗。我们提出了一项为期5年的混合方法研究,并将进行随机对照试验,随机化发生在护理团队和患者的水平。我们与5家威尼斯家庭诊所(VFC)诊所,洛杉矶县的两家医院以及科普Health Solutions合作。VFC是一个大型的联邦合格的健康中心(WHC),也是美国最大的免费诊所。我们的方法包括文件审查、焦点小组、访谈和调查,以获得有关采用过程和实施结果的数据;分析病人记录和对服务系统和病人结果的病人调查;分析提供者的财务记录和病人记录,并进行调查以估计成本。我们将招募400名诊断为OAUD的患者,并在3个月和12个月时对其进行随访。我们的具体目标是:1)测量ICC和E&R实施的过程和程度; 2)测试ICC与E&R策略在促进A.执行成果B.服务系统结果和C.病人的结果;和3)估计供应商成本为每一个策略。我们将实施结果定义为循证OAUD治疗的可接受性、采用性、适当性、可行性和可持续性的衡量标准。我们将服务系统结果定义为1)治疗质量的过程测量和2)治疗合并症。我们将患者结局定义为再入院、OAUD结局、患者功能、物质使用的负面后果和未满足的需求。我们将成本结果定义为启动成本、运营成本和医疗/精神病成本抵消。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Katherine E Watkins其他文献

Katherine E Watkins的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Katherine E Watkins', 18)}}的其他基金

REDUCING INAPPROPRIATE PRESCRIPTION OPIOID PRESCRIBING AT HOSPITAL DISCHARGE
减少出院时不适当的阿片类药物处方
  • 批准号:
    10171830
  • 财政年份:
    2019
  • 资助金额:
    $ 81.01万
  • 项目类别:
REDUCING INAPPROPRIATE PRESCRIPTION OPIOID PRESCRIBING AT HOSPITAL DISCHARGE
减少出院时不适当的阿片类药物处方
  • 批准号:
    10017035
  • 财政年份:
    2019
  • 资助金额:
    $ 81.01万
  • 项目类别:
REDUCING INAPPROPRIATE PRESCRIPTION OPIOID PRESCRIBING AT HOSPITAL DISCHARGE
减少出院时不适当的阿片类药物处方
  • 批准号:
    10621186
  • 财政年份:
    2019
  • 资助金额:
    $ 81.01万
  • 项目类别:
REDUCING INAPPROPRIATE PRESCRIPTION OPIOID PRESCRIBING AT HOSPITAL DISCHARGE
减少出院时不适当的阿片类药物处方
  • 批准号:
    10402368
  • 财政年份:
    2019
  • 资助金额:
    $ 81.01万
  • 项目类别:
Implementing Medication-Assisted Therapy for Substance Use Disorders in Mental Health
对心理健康中的药物使用障碍实施药物辅助治疗
  • 批准号:
    9755001
  • 财政年份:
    2019
  • 资助金额:
    $ 81.01万
  • 项目类别:
Implementing Medication-Assisted Therapy for Substance Use Disorders in Mental Health
对心理健康中的药物使用障碍实施药物辅助治疗
  • 批准号:
    9414164
  • 财政年份:
    2017
  • 资助金额:
    $ 81.01万
  • 项目类别:
Integrated Collaborative Care for Substance Use Disorders
药物滥用障碍的综合协作护理
  • 批准号:
    8492053
  • 财政年份:
    2012
  • 资助金额:
    $ 81.01万
  • 项目类别:
Integrated Collaborative Care for Substance Use Disorders
药物滥用障碍的综合协作护理
  • 批准号:
    8369268
  • 财政年份:
    2012
  • 资助金额:
    $ 81.01万
  • 项目类别:
Integrated Collaborative Care for Substance Use Disorders
药物滥用障碍的综合协作护理
  • 批准号:
    9094536
  • 财政年份:
    2012
  • 资助金额:
    $ 81.01万
  • 项目类别:
Using Technology To Deliver Brief Interventions in DUI Programs
利用技术对酒驾项目进行简短干预
  • 批准号:
    7817883
  • 财政年份:
    2009
  • 资助金额:
    $ 81.01万
  • 项目类别:

相似海外基金

Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
  • 批准号:
    24K16436
  • 财政年份:
    2024
  • 资助金额:
    $ 81.01万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
  • 批准号:
    10093543
  • 财政年份:
    2024
  • 资助金额:
    $ 81.01万
  • 项目类别:
    Collaborative R&D
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 81.01万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 81.01万
  • 项目类别:
    EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
  • 批准号:
    24K20973
  • 财政年份:
    2024
  • 资助金额:
    $ 81.01万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 81.01万
  • 项目类别:
    EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
  • 批准号:
    481560
  • 财政年份:
    2023
  • 资助金额:
    $ 81.01万
  • 项目类别:
    Operating Grants
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
  • 批准号:
    10075502
  • 财政年份:
    2023
  • 资助金额:
    $ 81.01万
  • 项目类别:
    Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
  • 批准号:
    10089082
  • 财政年份:
    2023
  • 资助金额:
    $ 81.01万
  • 项目类别:
    EU-Funded
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
  • 批准号:
    2321091
  • 财政年份:
    2023
  • 资助金额:
    $ 81.01万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了